Fulcrum Therapeutics reports Q1 EPS (25c), consensus (30c)

As of March 31, cash, cash equivalents, and marketable securities were $333.3M, compared to $352.3M as of December 31, 2025. The decrease of $19M was primarily due to cash used to fund operating activities in 2026. “The strength of the clinical data presented in the first quarter further reinforce our conviction in pociredir’s potential to address the underlying biology of sickle cell disease,” said Alex Sapir, Fulcrum’s president and CEO. “The magnitude of HbF induction and improvements in markers of hemolysis and anemia observed to date support our upcoming discussions with the FDA as we prepare for a potential registration-enabling study in the second half of 2026. With a strong balance sheet extending our cash runway into 2029, we are well positioned to advance pociredir through the next phase of clinical development.”